European patients begin receiving world’s first lung cancer vaccine in 'revolutionary' new trial.
👉 A lung cancer patient in the UK has become one of the first to participate in a groundbreaking trial for the world's first vaccine against the disease. Lung cancer is the leading cause of cancer death worldwide, responsible for approximately 1.8 million deaths in 2020.
👉 Of these, nearly a quarter of a million people - around 230 700 - are from the EU alone, representing nearly one in five cancer deaths in the region.
👉 The vaccine, known as BNT116 and developed by $BNTX (BioNTech SE-ADR) , utilises messenger RNA (mRNA) technology - similar to some COVID-19 vaccines - to help the immune system recognise and attack cancer cells.
👉The world-first jab is designed to target non-small cell lung cancer (NSCLC), which makes up 85% of all lung cancer cases. It works by presenting the patient’s immune system with information about common tumour markers associated with NSCLC.
👉 This specific targeting aims to destroy cancer cells while minimising damage to healthy cells, in contrast to the effects of chemotherapy.
👉 This ground-breaking study will involve about 130 patients with various stages of NSCLC, ranging from early stages before surgery or radiotherapy to late-stage disease, across 34 research sites in seven countries.
👉 As well as the UK, the trial is being rolled out in four other European countries - Germany, Spain, Poland, and Hungary - as well as the United States and Turkey.
👉 Dame Cally Palmer, NHS England’s national cancer director, stated that testing cancer vaccines could be "revolutionary" in preventing the recurrence of the disease by vaccinating individuals against their own cancers. "A cancer diagnosis is very worrying, but access to groundbreaking trials – alongside other innovations to diagnose and treat cancers earlier – provides hope," Palmer said.
👉 "We expect to see thousands more patients taking part in trials over the next few years".
Read more ❓ www.euronews.com/health/2024/08/23/european-patients-begin-receiving-worlds-first-lung-cancer-vaccine-in-revolutionary-trial
✨ @Cancer-Med Smart Portfolio consists of stocks of leading biotechnology companies that manufacture drugs used to treat the various types of cancer, as well as companies that have ongoing research programs dedicated to eradicating this disease, hopefully saving millions of lives or making living with the disease more manageable.
The minimum investment amount for the @Cancer-Med Smart Portfolio is $500.
Your capital is at risk. Past performance is not an indication of future results.... Show More
